Biotechnology in the Human Field from the Point of View of Bioethics
Akhlāq-i zīstī i.e., Bioethics Journal,
Vol. 13 No. 38 (1402),
28 May 2023
,
Page 1-13
https://doi.org/10.22037/bioeth.v13i38.41250
Abstract
Background and Aim: Although the issue of genetic manipulation offers a new perspective to medical science, it creates challenges in various fields, including bioethics, which are controversial. The purpose of this article is to investigate biotechnology in the human domain from the point of view of bioethics.
Methods: This article has been done using descriptive-analytical method along with the use of library resources.
Ethical Considerations: In present paper, the originality of the texts, honesty and trustworthiness are observed.
Results: In the process of biotechnology in the human domain, the important principles of bioethics should be considered. Observance of human dignity, the principle of free and informed consent, access to genetic resources and the fair sharing of the resulting benefits, and observance of the principle of caution and intervention for preventive, diagnostic or therapeutic purposes are among the most important principles of bioethics that must be followed in the processes caused by genetic manipulation. The issue of genetic manipulation and its effects on bioethics and human rights has been considered in some international documents, but the issue of the guarantee of implementation in these documents is either vague or not mentioned.
Conclusion: Genetic science as a science that causes the change and creation of animal and human phenomena and has important effects on the continuation of human life, should be considered in such a way that it includes both moral and religious concerns and provides conditions for the protection of human rights standards in order to improve the positive aspects of this field and improve human life.
- Biotechnology
- Human Domain
- Bioethics
- The Principle of Free and Informed Consent
How to Cite
References
Rahbarpour M. The concept of bioethics and its scope. Bioethics Quarterly. 2011; 1(1): 13-48. [Persian]
Rahnama H. Bioethics and transgenic products. Ethics in Science and Technology Quarterly. 2008; 3(1-2): 1-14. [Persian]
Hadjantonakis AK, Papaioannou VE. Can mammalian cloning combined with embryonic stem cell technologies be used to treat human diseases? Genome biology. 2002; 3(8):1-6.
Hwang WS, Roh SI, Lee BC, Kang SK, Kwon DK, Kim S, et al. Patient-specific embryonic stem cells derived from human SCNT blastocysts. Science. 2005; 308(5729): 1777-1783.
Robertson JA. Embryo Stem Cell Research: Ten Years of Controversy. The Journal of Law, Medicine & Ethics. 2010; 2(38): 191-203.
Rhind SM, Taylor JE, De Sousa PA, King TJ, McGarry MW. Human cloning: Can it be made safe?. Nature Rev Genet. 2003; 4(11): 55-64.
Wilmut I, Beaujean N, De Sousa PA, Dinnyes A, King TJ, Paterson LA, Wells DN, Young LE. Somatic cell nuclear transfer. Nature. 2002; 419(6907): 583-587.
Gorbannia N. Regarding the Universal Declaration of Bioethics and Human Rights. Ethics in Science and Technology Quarterly. 2009; 4(1): 133-137. [Persian]
Straus SB, Tan HM, Boerjan W. Strangled at Birth? Forest Biotech and the Convention on Biological Diversity. Nature Biotecnology. 2009; 27(6): 519-527.
West C. Economics and Ethics in the Genetic Engineering of Animals. Harvard Journal of Law and Biotechnology. 2006; 19(2): 413-442.
Tladi D. Civil liability in the Context of the Cartagena Protocol to be or not to be (Binding)? International Environmental Agreements. Politics Law and Economics. 2010; 10(1): 15-27.
Ghareyazi B, Mottaghi A, Vishlaghi N, Rashedi H. Biosafety at International Agreements/ Organizations. Medical Law Quarterly. 2010; 4(12): 131-147. [Persian]
Bell DE. Need for a Biosafety Protocol Finally Agreed upon. Times. 1995; 28: 31-38.
Jordan WC, Verspoor E, Youngson AF. The Effect of Natural Selection on Estimates of Genetic Divergence among Populations of the Atlantic salmon. Journal of Fish Biology.1997; 51(3): 546-560.
Annas GJ, Andrews LB, Isasi RM. Protecting the endangered human: toward an international treaty prohibiting cloning and inheritable alterations. American journal of law & medicine. 2002; 28(2-3):151-78.
Ranjbarian AH, Seif Z. Human Rights Challenges of Human Simulation. Law Journal. 2018; 39(1): 129-158. [Persian]
Naqibzadeh A. The impact of changes in the international system on the concept of human rights. Political and Economic Information Monthly. 2001; 95(171-172): 30-41. [Persian]
Bossart J, Pearson B. Commercialization of gene therapy-the evolution of licensing and rights issues. Trends in biotechnology. 1995; 13(8): 290-294.
Marks SP. Human rights assumptions of restrictive and permissive approaches to human reproductive cloning. Health & Hum. Rts. 2002; 6: 80.
De Sá Mde F, de Oliveiro Naves BT. Embryonic stem cell research in Brazil and the (UN) constitutionality of article 5 of the biosafety act (Part I). Revista de Derecho y Genoma Humano= Law and the Human Genome Review. 2008; 1(28):177-191.
Abbasi M. Human simulation is a new challenge to ethics and human rights. Medical Law Quarterly. 2008; 5(7): 11-46. [Persian]
Epstein G. Controlling Biological Warfare Threats. Critical Reviews in Microbiology. 2001; 27(4): 321-354.
Ghorbani AA. Human Cloning and Criminal Policy. Medical Law Quarterly. 2010; 4(13): 161-190. [Persian]
- Abstract Viewed: 330 times
- PDF (فارسی) Downloaded: 152 times